Icon

Evotaz - (EQ 300mg Base; 150mg, Tablet, Oral)

ATAZANAVIR SULFATE; COBICISTAT BRISTOL MYERS SQUIBB
EQ 300mg Base; 150mg, Tablet, Oral
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
None
None None
HIV-1 infection in combination with other antiretroviral agents.
Yes
***** ** *** ***** ** **** **** ** **** ****** ******* **/**/**** *** *** ************ *********. ** ** ********* ** **** **** ***** *** *** ***** ******* ********** *** **** *.*. *********** **/**/****; *********** **/**/**** ** ***** ***** *** ***** * **** ***, **** ***** ****** ****** ****** **** **, ****. ****** *** ****** ** ** ****** ****, ********** *** ********* **** ***** ***** *** ***** ** ********* *** *** *****. ** ****** ***** ** ****** ********* ****** **** ** *** ***** ****** ********** ********** ******* ** **** ****.
Evotaz Patent 1 Patent 2 Patent 3
***** ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
***** *** \ ** *** **, **** ******* **** ***** *** **** (******** ******)
  1. *** *, **** : ***** ***** **** ** **** ****** ******* **/**/****.
  2. *** **, **** : ****** ***** * **** ******* ***** ** ******** ***** ** ******** ******** ** **** ********.
  3. *** **, **** : ********** ********* **** ***** *** ****** '*** (**** *, ****) *.*. *** **** ****** ** ****.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.